12/13
07:01 am
gnlx
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
Medium
Report
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright
11/15
08:03 am
gnlx
Genelux Co. (NASDAQ: GNLX) had its price target lowered by analysts at HC Wainwright from $32.00 to $30.00. They now have a "buy" rating on the stock.
High
Report
Genelux Co. (NASDAQ: GNLX) had its price target lowered by analysts at HC Wainwright from $32.00 to $30.00. They now have a "buy" rating on the stock.
11/15
05:46 am
gnlx
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts [Yahoo! Finance]
High
Report
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts [Yahoo! Finance]
11/14
04:17 pm
gnlx
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates [Yahoo! Finance]
High
Report
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates [Yahoo! Finance]
11/14
04:05 pm
gnlx
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
High
Report
Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates
11/6
04:01 pm
gnlx
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
Medium
Report
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference
10/29
07:09 am
gnlx
Genelux Co. (NASDAQ: GNLX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $8.00 price target on the stock.
Low
Report
Genelux Co. (NASDAQ: GNLX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $8.00 price target on the stock.
10/22
04:01 pm
gnlx
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
High
Report
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer
10/9
04:15 pm
gnlx
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit
Low
Report
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit